Evidence map›Paper›PMID 26604688›Full record

ReviewDrug design, development and therapy2015

Critical appraisal of Timothy grass pollen extract GRAZAX in the management of allergic rhinitis.

Alessandra Scaparrotta, Marina Attanasi, Marianna I Petrosino, Paola Di Filippo, Sabrina Di Pillo, Francesco Chiarelli

Open access · goldAbstract readReview
In one paragraph

Review in Drug design, development and therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 8 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Alessandra ScaparrottaDepartment of Pediatrics, University of Chieti, Chieti, Italy.
Marina AttanasiDepartment of Pediatrics, University of Chieti, Chieti, Italy.
Marianna I PetrosinoDepartment of Pediatrics, University of Chieti, Chieti, Italy.
Paola Di FilippoDepartment of Pediatrics, University of Chieti, Chieti, Italy.
Sabrina Di PilloDepartment of Pediatrics, University of Chieti, Chieti, Italy.
Francesco ChiarelliDepartment of Pediatrics, University of Chieti, Chieti, Italy.
University of Chieti-Pescara · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergic rhinitis is one of the most common diseases of adult and pediatric age, associated with grass pollen (GP) allergy in >50% cases, with a consistent impact on quality of life of affected patients. A grass allergen tablet, containing standardized extract derived from Timothy grass (Phleum pratense) pollen and ~15 μg major allergen P. pratense (rPhl p 5), may be the future of allergen-specific immunotherapy (IT) for GP allergy. The aim of this review was to critically evaluate the role of Timothy GP extract IT for the management of allergic rhinitis. For this purpose, we have tried to analyze potential mechanisms of action at the basis of Timothy GP extract, we have reviewed efficacy studies to establish potential benefits and clinical response, and we have also evaluated safety and tolerability profiles and patient focus perspective, such as quality of life, satisfaction and acceptability, and compliance to this IT.

Indexed as

AdultChildDesensitization, ImmunologicHumansPhleumPlant ExtractsPollenQuality of LifeRhinitis, Allergic, SeasonalGrazaxPlant Extractsallergic rhinitiscomplianceefficacyGrazaxsafetyTimothy grass pollen extract

Identifiers

PMID26604688
PMCPMC4639524
OpenAlexW2181690080

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.